Neonatal Adaptation Issues After Maternal Exposure to Prescription Drugs: Withdrawal Syndromes and Residual Pharmacological Effects

被引:0
作者
Irma Convertino
Alice Capogrosso Sansone
Alessandra Marino
Maria T. Galiulo
Stefania Mantarro
Luca Antonioli
Matteo Fornai
Corrado Blandizzi
Marco Tuccori
机构
[1] University of Pisa,Department of Clinical and Experimental Medicine
[2] University Hospital of Pisa,Tuscan Regional Centre for Pharmacovigilance, Unit of Adverse Drug Reaction Monitoring
来源
Drug Safety | 2016年 / 39卷
关键词
Valproic Acid; Buprenorphine; Neonatal Intensive Care Unit; Withdrawal Symptom; Withdrawal Syndrome;
D O I
暂无
中图分类号
学科分类号
摘要
Exposure to drugs during pregnancy has the potential to harm offspring. Teratogenic effects are the most feared adverse outcomes in newborns; however, a wide spectrum of less known, usually reversible and often acute, neonatal adverse events can also occur due to drug intake by mothers during pregnancy, particularly in close proximity to delivery. This narrative review is aimed at the description of drugs and drug classes for which licit maternal use in the predelivery period has been associated with neonatal non-teratogenic disorders. For each drug class, epidemiology, clinical features, biological mechanism and management of these adverse reactions have been discussed in detail. Although these adverse reactions have been described mainly for substances used illicitly for recreational purposes, several prescription drugs have also been involved; these include mainly psychotropic medications such as opioids, antidepressants, antiepileptics and antipsychotics. These effects can be partly explained by withdrawal syndromes (defined also as ‘neonatal abstinence syndrome’) caused by the delivery-related discontinuation of the drug disposition from the mother to the fetus, with symptoms that may include feeding disorders, tremors, irritability, hypotonia/hypertonia, vomiting and persistent crying, occurring a few hours to 1 month after delivery. Otherwise, neonatal neurological and behavioral effects can also be caused by a residual pharmacological effect due to an accumulation of the drug in the blood and tissues of the newborn, with various symptoms related to the toxic effects of the specific drug class, usually developing a few hours after birth. With few exceptions, validated protocols for the assessment and management of withdrawal or residual pharmacological effects of these drugs in neonates are often lacking or incomplete. Spontaneous reporting of these adverse reactions seems limited, although it might represent a useful tool for improving our knowledge about drug-induced neonatal syndromes.
引用
收藏
页码:903 / 924
页数:21
相关论文
共 1026 条
  • [1] Friedman JM(2012)ABCDXXX: The obscenity of postmarketing surveillance for teratogenic effects Birth Defects Res Part A Clin Mol Teratol. 94 670-676
  • [2] Kocherlakota P(2014)Neonatal abstinence syndrome Pediatrics 134 e547-e561
  • [3] Edwards IR(2000)Adverse drug reactions: definitions, diagnosis, and management Lancet 356 1255-1259
  • [4] Aronson JK(2012)Adverse drug reactions in newborns, infants and toddlers: pediatric pharmacovigilance between present and future Expert Opinion Drug Saf. 11 95-105
  • [5] Fabiano V(2006)A new indication for therapeutic drug monitoring in the neonate Ther Drug Monit 28 1-17
  • [6] Mameli C(2015)Neonatal abstinence syndrome: Historical perspective, current focus, future directions Prev Med 80 12-3
  • [7] Zuccotti GV(2016)Neonatal withdrawal syndrome: reaching epidemic proportions across the globe Arch Dis Child Fetal Neonatal Ed 101 2-350
  • [8] Koren G(2009)Diagnosis and management of poor neonatal adaptation syndrome in newborns exposed in utero to selective seretonin/norepinephrine reuptake inhibitors J Obstet Gynecol Can 31 348-751
  • [9] Jones HE(2008)Serotonin reuptake inhibitor use in pregnancy and the neonatal behavioral syndrome J Matern Fetal Neonatal Med. 21 745-354
  • [10] Fielder A(2008)Fetal and neonatal effects of maternal drug treatment for depression Semin Perinatol 32 350-18